MedWatch

“We are not doing too bad in Denmark”

The US biotech industry is probably the most important driving force on the global market. But are Danish companies really taking advantage of that. No, says top-exec Jan Leschly. But the biotech experts of the Medwatch Panel disagree.

Danish biotech companies have one major problem. Their research is top-shelf, but we have a hard time continuing the development of the products and bringing them through clinical trials, says Jan Leschly, partner in the American venture fund Care Capital. Many biotech companies underestimate the value of bringing in outside expertise to attract US capital, and generally speaking there is not enough focus on the US, he believes.

Do you agree with the American executive? Why or why not?

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier